Lauren Merendino
Directeur/Membre du Conseil chez ESSA PHARMA INC.
Fortune : - $ au 31/05/2024
Postes actifs de Lauren Merendino
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| DAY ONE BIOPHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/05/2023 | - |
| ESSA PHARMA INC. | Directeur/Membre du Conseil | 06/06/2023 | - |
| Independent Dir/Board Member | 06/06/2023 | - |
Historique de carrière de Lauren Merendino
Anciens postes connus de Lauren Merendino
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Corporate Officer/Principal | 01/09/2018 | 01/04/2021 |
Myovant Sciences, Inc.
 Myovant Sciences, Inc. Medical SpecialtiesHealth Technology Myovant Sciences, Inc. offers therapeutics for women's health and prostate cancer. The company is headquartered in New York, NY. | Corporate Officer/Principal | 01/04/2021 | - |
| MYOVANT SCIENCES LTD. | Corporate Officer/Principal | 01/04/2021 | - |
Formation de Lauren Merendino
| The Pennsylvania State University | Undergraduate Degree |
| New York University | Masters Business Admin |
Statistiques
Internationale
| Etats-Unis | 6 |
| Royaume-Uni | 2 |
| Canada | 2 |
Opérationnelle
| Corporate Officer/Principal | 4 |
| Undergraduate Degree | 1 |
| Masters Business Admin | 1 |
Sectorielle
| Health Technology | 6 |
| Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| DAY ONE BIOPHARMACEUTICALS, INC. | Health Technology |
| ESSA PHARMA INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Myovant Sciences Ltd.
 Myovant Sciences Ltd. BiotechnologyHealth Technology Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for the treatment of women's health and endocrine diseases. It offers ORGOVYXTM, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer, and MYFEMBREE, which is taken for the management of heavy menstrual bleeding associated with uterine fibroids. The company was founded on February 2, 2016 and is headquartered in London, the United Kingdom. | Health Technology |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
Myovant Sciences, Inc.
Myovant Sciences, Inc. Medical SpecialtiesHealth Technology Myovant Sciences, Inc. offers therapeutics for women's health and prostate cancer. The company is headquartered in New York, NY. | Health Technology |
- Bourse
- Insiders
- Lauren Merendino
- Expérience
